Mitsui Chemicals Inc (MITUY) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Mitsui Chemicals Inc stock $12.71, price $10.89, upside +16.7%, quality 57 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range $4.42 – $14.68 · fair‑value band $9.53 – $15.89 · the $10.89 price screens below the $12.71 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 3, 2026.
Follow Mitsui Chemicals Inc ADR in your weekly email
Every Wednesday you see whether Mitsui Chemicals Inc ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Mitsui Chemicals, Inc. engages in the mobility, life and health care, basic and green materials, ICT, and other businesses worldwide.
Show moreShow less
The company offers vision care materials, nonwoven fabrics and personal care materials, agricultural chemicals, and oral care materials; and elastomers, performance and polypropylene compounds, and other materials.
It also provides semiconductor solutions, such as electronic component processing materials, optical materials, and lithium-ion battery materials; functional food packaging materials; imaging solutions, such as lens materials, materials for reflective films, and LCD and OLED sealing materials; battery material solutions; and converting solutions, including heat sealants, barrier coating materials, and packaging adhesives.
In addition, the company offers petrochemicals, which comprise ethylene, propylene, high- and low-density polyethylene; basic chemicals, such as phenol, bisphenol, acetone, isopropyl alcohol, methyl isobutyl ketone, purified terephthalic acid, PET resin, ethylene oxide and glycol, hydroquinone, meta/para-cresol, ammonia, urea, and melamine; and polyurethane raw materials, as well as develops DNA microarrays.
Further, it provides life care solutions, such as ophthalmic lens materials, photochromic lens materials, coating materials, nonwovens, breathable films, filtration devise, acrylamide, methacrylamide, and synthetic pulp; agrochemical products, including insecticides, fungicides, herbicides, non-crop specialty chemicals, pet medication ingredients; and medical solutions, restoratives, adhesives, artificial teeth, denture materials, impression, digital equipment/materials, medical materials, genetic testing, and contract genetic analysis services.
It sells its products in Japan, China, Asia, the Americas, Europe, and internationally. Mitsui Chemicals, Inc. was founded in 1892 and is headquartered in Tokyo, Japan.
Stock analysis
Mitsui Chemicals Inc (MITUY) currently trades at $10.89, while our model-based Fair Value estimate is $12.71, implying the stock looks roughly 14% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $14.41 per share, and 11 of the 24 models we run sit above the $10.89 price.
Bear case: the Dividend Discount group reads lowest at $4.95, and 13 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $9.53 (bear) to $15.89 (bull), the price of $10.89 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Mitsui Chemicals Inc ADR reported revenue of ¥1.8T in FY2026 versus ¥1.6T in FY2022, a compound +2.3%/yr. Reported net income was ¥36.5B in FY2026, compounding −24.1%/yr from FY2022.
Key figures
Market cap $5.0B Mid · P/E ratio 9.5 · P/S ratio 0.20 · EPS (TTM) $1.15 · Dividend yield 3.7% · Net margin 2.1% · Return on equity 8.1% · Return on assets (EBIT) 4.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at 17%, MITUY screens cheaper than that median.
Fair Value models
Bear$9.53Fair Value $12.71Bull$15.89
Price $10.89 · Upside +16.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then ($0.6995 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF$10.21$15.44$23.1079
Growth DCF$10.65$15.62$22.5777
Residual Income$11.39$11.39$11.8576
All 24 models by family
DCF Models
FCF DCF$10.21$15.44$23.1079
Owner Earnings$7.67$11.93$18.1775
5Y Revenue Exit$7.99$12.99$19.2671
5Y EBITDA Exit$12.42$20.69$30.1374
5Y P/E Exit$6.13$9.75$13.4070
10Y Revenue Exit$8.43$12.96$18.2766
10Y EBITDA Exit$11.44$18.05$25.8667
10Y P/E Exit$7.58$10.81$14.1864
Earnings-Based
Graham-Dodd$4.33$8.69$10.9266
EPV$4.90$6.25$7.4373
Dividend Discount
Gordon GGM$3.50$5.00$6.5369
DDM Multi-Stage$3.50$4.90$6.4967
Multiples
P/E Multiple$8.11$10.82$13.5263
P/S Multiple$8.11$10.82$13.5257
P/B Multiple$30.25$40.33$50.4255
EV/EBIT$5.17$9.31$13.4662
EV/EBITDA$12.44$19.00$25.5766
EV/Revenue$3.51$8.13$12.7550
Asset-Based
NCAV (Graham)$0.0300$0.0500$0.060054
Growth DCF
Growth DCF$10.65$15.62$22.5777
Rev-Margin DCF$7.99$13.20$18.8971
Economic Profit
Residual Income$11.39$11.39$11.8576
ROIC Compounder$4.90$6.25$7.4371
Growth Earnings
Growth-Adj P/E$5.96$8.51$11.0667
The fair value above starts from this blend and is adjusted for a cyclical trough year.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Start year 2021 (pandemic). Over 10 years: +2.8% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+9.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.2%
Dividend (yield on the price)3.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6.2% vs 13.4%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 5%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about −1.4% a year for the price and +0.0% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (38 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: The push into life and healthcare via specialized culture plates forms the main strength, while persistently low returns on equity and assets point to the central weakness of a weak moat.
Main risk: Failure of the biotech tools to move beyond niche laboratory applications would limit scale in the life and healthcare solutions segment.
Mitsui Chemicals recently launched InnoCell P-Type culture plates that use its oxygen-permeable materials to support more uniform and functional organoid growth for drug discovery research. This step builds on the push into life and healthcare solutions while the core remains specialty chemicals. Will these targeted biotech tools generate meaningful scale or stay confined to niche lab use?
Compare Mitsui Chemicals Inc ADR with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 727 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside+16.7% · Top 25%
Profitability
Return on equity (12 months)8.1% · Above median
Return on assets1.7% · Below median
Net margin (12 months)3.8% · Below median
Operating margin (12 months)9.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)10.8% · Below median
Dividend yield (12 months)3.7% · Top 25%
Balance sheet
Debt / equity0.51× · Highest 25%
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Mitsui Chemicals Inc (MITUY) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of $12.71 versus a price of $10.89, about +17% upside (undervalued).
What is the fair value of MITUY?
Our model-based fair value for Mitsui Chemicals Inc is $12.71 (as of Nov 3, 2026), built from audited fundamentals. The current price: $10.89.
What is the quality score of MITUY?
Mitsui Chemicals Inc has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mitsui Chemicals Inc (MITUY)?
Our model-based price target is the fair value of $12.71 (as of Nov 3, 2026) from 24 valuation models. Cautious scenario $9.53, optimistic scenario $15.89. It is a calculation from audited fundamentals, not an analyst target.
What is the Mitsui Chemicals Inc ADR stock forecast for 2026?
Our models put fair value at $12.71, about +17% upside versus a price of $10.89 (undervalued). Cautious scenario $9.53, optimistic scenario $15.89. The calculation is refreshed regularly with new filings.
What is the revenue of Mitsui Chemicals Inc (MITUY)?
Mitsui Chemicals Inc reported trailing-twelve-month revenue of about ¥1.7T (latest available figure, as of Nov 3, 2026).
Does Mitsui Chemicals Inc ADR pay a dividend?
Mitsui Chemicals Inc currently shows a dividend yield of 3.66% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Mitsui Chemicals Inc (MITUY) and when is the ex-dividend date?
Mitsui Chemicals Inc has a dividend yield of 3.7%. The last ex-dividend date was Mar 31, 2026. A dividend has been paid every year since at least 2011. The payout ratio is 62.6% of earnings. Free cash flow covers the dividend 3.94 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Mitsui Chemicals Inc (MITUY)?
For today's price to be fair in a discounted-cash-flow model, Mitsui Chemicals Inc would have to grow free cash flow by +0.7 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.9 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of MITUY use?
Our models discount Mitsui Chemicals Inc at 9.2 %: a base by market capitalisation (mid), damped by beta 0.78, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Mitsui Chemicals Inc that is +0.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has Mitsui Chemicals Inc (MITUY) delivered so far?
Over the past 5 years revenue at Mitsui Chemicals Inc grew +7.9 % a year. The price currently implies free-cash-flow growth of +0.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Mitsui Chemicals Inc (MITUY) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into Mitsui Chemicals Inc (+0.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Mitsui Chemicals Inc (MITUY)?
The free-cash-flow yield on the price is 14.41 %: that much free cash flow Mitsui Chemicals Inc produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Mitsui Chemicals Inc (MITUY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mitsui Chemicals Inc it is $12.71 per share (as of Nov 3, 2026), against a price of $10.89. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Mitsui Chemicals Inc ADR stock overvalued or undervalued in 2026?
As of Nov 3, 2026, MITUY trades below its calculated fair value: price $10.89, fair value $12.71, a gap of about +17% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MITUY?
No. The price is what the market pays today ($10.89); the fair value is what the company's own numbers justify ($12.71). For Mitsui Chemicals Inc the two are $1.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mitsui Chemicals Inc ADR worth?
The market values Mitsui Chemicals Inc at about $5.0B (market capitalisation, as of Nov 3, 2026). Per share that is $10.89; our models calculate a fair value of $12.71 per share.
What do the bullish and bearish scenarios say about MITUY?
Our models span a range for Mitsui Chemicals Inc: cautious scenario $9.53, base $12.71, optimistic $15.89 per share (as of Nov 3, 2026, price $10.89). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MITUY?
Mitsui Chemicals Inc trades at a price-to-earnings ratio of 9.5 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $12.71 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2018 to 2026), reported earnings: 18.0. Other multiples: P/B 0.9, P/S 0.5, EV/EBITDA 5.1.
How solid is the balance sheet of Mitsui Chemicals Inc (MITUY)?
Balance-sheet figures for Mitsui Chemicals Inc (as of Nov 3, 2026): return on equity 8.1%, debt of 0.51 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is MITUY from its 52-week high?
Mitsui Chemicals Inc trades at $10.89, about 26% below its 52-week high of $14.68 and at the low of $10.89 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $12.71 is for.
Which stocks are comparable to Mitsui Chemicals Inc ADR?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mitsui Chemicals Inc ADR stock attractive at the current price?
The data as of Nov 3, 2026: price $10.89, calculated fair value $12.71 (+17%), Quality Score 57/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MITUY calculated?
We run Mitsui Chemicals Inc through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $12.71 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Mitsui Chemicals Inc currently trades 14% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mitsui Chemicals Inc (MITUY)?
The closing price on Nov 6, 2026 was $10.89. Our model-based fair value is $12.71, about +17% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mitsui Chemicals Inc ADR right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Mitsui Chemicals Inc (MITUY) come from?
Earnings per share at Mitsui Chemicals Inc grew +10.3 % a year from 2015 to 2026. Broken into its drivers: revenue per share +12.0 %, EBIT margin −1.5 %, tax rate −2.0 %, residual (interest, one-offs) +2.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Mitsui Chemicals Inc
How large is the market capitalisation of Mitsui Chemicals Inc (MITUY)?
The market capitalisation of Mitsui Chemicals Inc is $5.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mitsui Chemicals Inc (MITUY)?
The price-to-sales ratio of Mitsui Chemicals Inc is 0.20 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mitsui Chemicals Inc (MITUY)?
Earnings per share at Mitsui Chemicals Inc are $1.15 (price ÷ EPS = P/E 9.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Mitsui Chemicals Inc (MITUY)?
The dividend yield of Mitsui Chemicals Inc is 3.7% (payout 34.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Mitsui Chemicals Inc (MITUY)?
The net margin of Mitsui Chemicals Inc is 2.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mitsui Chemicals Inc (MITUY)?
The return on equity (ROE) of Mitsui Chemicals Inc is 8.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mitsui Chemicals Inc (MITUY)?
On an EBIT basis the return on assets of Mitsui Chemicals Inc is 4.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mitsui Chemicals Inc (MITUY)?
The operating margin of Mitsui Chemicals Inc is 9.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mitsui Chemicals Inc (MITUY)?
Revenue at Mitsui Chemicals Inc is growing +10.8% versus a year earlier (3y avg −2.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Mitsui Chemicals Inc (MITUY)?
Earnings per share at Mitsui Chemicals Inc are growing +44.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Mitsui Chemicals Inc (MITUY) carry?
The net debt of Mitsui Chemicals Inc is ¥559B (fiscal year 2026, ≈ 6.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Mitsui Chemicals Inc ADR in the live analysis
One click puts Mitsui Chemicals Inc ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 3, 2026